Defining the Next Era of Cancer Therapeutics
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an outstanding group of regional industry leaders...
Continue ReadingKnowledge Library
Defining the Next Era of Cancer Therapeutics
Building on the momentum of AACR 2026, WuXi AppTec was honored to host an exceptional group of regional industry leaders...
Continue Reading
Targeting ER Mutations and Drug Resistance
Targeting ER Mutations and Drug Resistance: R&D Strategies and Comprehensive Preclinical Evaluation of Novel ER Degraders Introduction Estrogen receptor (ER)-positive...
Continue Reading
PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...
Continue Reading
Novel E3 Ligase to Support Targeted Protein Degradation
Targeted protein degradation (TPD) continues to expand the possibilities for next-generation therapeutics, and identifying novel E3 ligases remains an important...
Continue Reading
Mechanistic Profiling of ADC-resistant Cancer Cell Lines
Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...
Continue Reading
DEL and Display Technologies Empower Discovery of Peptide Drugs
In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...
Continue Reading
Supporting Discovery of mRNA Drugs
Unlike conventional protein-targeted therapies, which often provide only transient effects, nucleic acid therapeutics have the potential for long-lasting effects and...
Continue Reading
Advanced Conjugate Delivery Systems for Oligonucleotides
Oligonucleotide therapeutics represent a transformative treatment modality with demonstrated potential across metabolic disorders, CNS diseases, muscular dystrophies, and a broad...
Continue Reading